| Source: |
| Type: type of cell death |
| Situation in which a cell actively pursues a course toward death upon receiving certain stimuli. Cancer is one of the scenarios where too little apoptosis occurs, resulting in malignant cells that will not die. |
| 7906- | IVT, | Isovitexin accelerates diabetic wound repair via coordinated angiogenesis and collagen remodeling: Mechanistic insights from cellular and streptozotocin-induced SD rat models |
| - | in-vivo, | Nor, | NA |
| 7892- | IVT, | Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway |
| - | in-vitro, | Nor, | HCEC 1CT | - | in-vivo, | Colon, | NA |
| 7893- | IVT, | Isovitexin (IV) induces apoptosis and autophagy in liver cancer cells through endoplasmic reticulum stress |
| - | vitro+vivo, | Liver, | NA |
| 7888- | IVT, | Isovitexin Exerts Anti-Inflammatory and Anti-Oxidant Activities on Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting MAPK and NF-κB and Activating HO-1/Nrf2 Pathways |
| - | vitro+vivo, | Nor, | NA |
| 8007- | JG, | Juglone reduces growth and migration of U251 glioblastoma cells and disrupts angiogenesis |
| - | in-vitro, | GBM, | U251 |
| 7965- | JG, | Mechanistic investigation of Juglone (5-hydroxy-1,4-naphthoquinone) as an anti-cancer agent in human colorectal cancer HCT116 and HT-29 cell lines |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 |
| 7961- | JG, | Juglone Inhibits Tumor Metastasis by Regulating Stemness Characteristics and the Epithelial-to-Mesenchymal Transition in Cancer Cells both in Vitro and in Vivo |
| - | vitro+vivo, | BC, | MCF7 | - | in-vitro, | BC, | 4T1 | - | vitro+vivo, | CRC, | HCT116 |
| 5118- | JG, | Juglone induces apoptosis and autophagy via modulation of mitogen-activated protein kinase pathways in human hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | HepG2 |
| 5099- | JG, | Juglone induces ferroptosis in glioblastoma cells by inhibiting the Nrf2-GPX4 axis through the phosphorylation of p38MAPK |
| - | vitro+vivo, | GBM, | LN229 | - | vitro+vivo, | GBM, | T98G |
| 5115- | JG, | Natural Products to Fight Cancer: A Focus on Juglans regia |
| - | Review, | Var, | NA |
| 5117- | JG, | https://pubmed.ncbi.nlm.nih.gov/31283929/ |
| - | vitro+vivo, | Liver, | NA |
| 1918- | JG, | ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro |
| - | in-vitro, | Liver, | HepG2 | - | in-vivo, | NA, | NA |
| 1927- | JG, | Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway |
| - | in-vitro, | GC, | SGC-7901 |
| 1924- | JG, | Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway |
| - | in-vitro, | Lung, | A549 |
| 1922- | JG, | Juglone induces apoptosis of tumor stem-like cells through ROS-p38 pathway in glioblastoma |
| - | in-vitro, | GBM, | U87MG |
| 1919- | JG, | The Anti-Glioma Effect of Juglone Derivatives through ROS Generation |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 8085- | KAE, | Effects and Mechanisms of Kaempferol in the Management of Cancers through Modulation of Inflammation and Signal Transduction Pathways |
| - | Review, | Var, | NA |
| 8087- | KAE, | Therapeutic Importance of Kaempferol in the Treatment of Cancer through the Modulation of Cell Signalling Pathways |
| - | Review, | Var, | NA |
| 8092- | KAE, | Kaempferol Reverses Aerobic Glycolysis via miR-339-5p-Mediated PKM Alternative Splicing in Colon Cancer Cells |
| - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Colon, | DLD1 |
| 8093- | KAE, | Kaempferol inhibits Nrf2 signalling pathway via downregulation of Nrf2 mRNA and induces apoptosis in NSCLC cells |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H460 |
| 8096- | KAE, | 5-FU, | Synergistic effect of kaempferol and 5‑fluorouracil on the growth of colorectal cancer cells by regulating the PI3K/Akt signaling pathway |
| - | in-vitro, | CRC, | HCT8 | - | in-vitro, | CRC, | HCT8 |
| 8097- | KAE, | The Phenolic compound Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells |
| - | in-vitro, | CRC, | LS174T |
| 8100- | KAE, | Kaempferol increases apoptosis in human cervical cancer HeLa cells via PI3K/AKT and telomerase pathways |
| - | in-vitro, | Cerv, | HeLa |
| 8102- | KAE, | Kaempferol inhibits gastric cancer tumor growth: An in vitro and in vivo study |
| - | vitro+vivo, | GC, | MKN-28 | - | vitro+vivo, | GC, | SGC-7901 | - | in-vitro, | GC, | GES-1 |
| 8105- | KAE, | Chemo-preventive and therapeutic effect of the dietary flavonoid kaempferol: A comprehensive review |
| - | Review, | Var, | NA |
| - | in-vitro, | Melanoma, | A375 |
| - | in-vitro, | Ovarian, | A2780S |
| 8071- | KAE, | Cellular reprogramming and signaling control by kaempferol in colorectal cancer |
| - | Review, | CRC, | NA |
| 8059- | KAE, | Kaempferol Inhibits Cervical Cancer Cells by Inducing Apoptosis and Autophagy via Inactivation of the PI3K/AKT/mTOR Signaling Pathway |
| - | in-vitro, | Cerv, | KB |
| 8061- | KAE, | Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathway |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | OVCAR-3 |
| 8064- | KAE, | Kaempferol Inhibits Pancreatic Cancer Cell Growth and Migration through the Blockade of EGFR-Related Pathway In Vitro |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | SNU-213 |
| 8067- | KAE, | Cisplatin, | Kaempferol Induces Cell Death and Sensitizes Human Head and Neck Squamous Cell Carcinoma Cell Lines to Cisplatin |
| - | in-vitro, | HNSCC, | NA |
| 8070- | KAE, | Kaempferol: Paving the path for advanced treatments in aging-related diseases |
| - | Review, | AD, | NA |
| 8072- | KAE, | Natural defense against colorectal cancer: the effects of kaempferol on epigenetics, apoptosis, inflammation, oxidative stress, and cell proliferation |
| - | Review, | CRC, | NA |
| 8075- | KAE, | QC, | Systematic review on anticancer potential of Kaempferol and quercetin against lung, breast, and colorectal cancers with emphasis on in vitro and in vivo studies |
| - | Review, | Var, | NA |
| 8077- | KAE, | Kaempferol exerts anti-colorectal cancer effects through its multi-target mediated glucose metabolism remodeling |
| - | in-vitro, | CRC, | NA |
| 8078- | KAE, | Kaempferol induces mitophagy and disrupts iron metabolism via SFXN2 leading to apoptosis in multiple myeloma cells |
| - | in-vitro, | Mye, | NA |
| 8079- | KAE, | Endoplasmic Reticulum Stress-Mediated Apoptosis Induced by Kaempferol in Colorectal Cancer Cells |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HUH7 | - | in-vitro, | Cerv, | HeLa |
| 8081- | KAE, | The Anticancer Effects and Therapeutic Potential of Kaempferol in Triple-Negative Breast Cancer |
| - | Review, | BC, | NA |
| 8053- | KAE, | Kaempferol as a therapeutic agent in Alzheimer's disease: Evidence from preclinical studies |
| - | Review, | AD, | NA |
| 8056- | KAE, | Kaempferol: advances in biosynthesis, molecular mechanisms, and therapeutic applications |
| - | Review, | Var, | NA | - | Review, | Diabetic, | NA |
| 8147- | Lae, | Mechanisms underlying the therapeutic effects of Amygdalin in treating Cervical Cancer based on multi-omics analysis |
| - | in-vitro, | Cerv, | Ca9-22 | - | in-vitro, | Cerv, | HeLa |
| 8148- | lamb, | Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells |
| - | in-vitro, | Pca, | LNCaP |
| 8161- | LapC, | Lapachol is a novel ribosomal protein S6 kinase 2 inhibitor that suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells |
| - | in-vitro, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE450 | - | in-vitro, | ESCC, | KYSE-510 |
| 8162- | LapC, | Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2 |
| - | in-vitro, | Melanoma, | MEL526 | - | in-vitro, | Melanoma, | MEL697 | - | in-vitro, | Melanoma, | MEL103 |
| 8164- | LapC, | Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II |
| - | vitro+vivo, | GBM, | NA |
| 8175- | Las, | Lasiodin Inhibits Proliferation of Human Nasopharyngeal Carcinoma Cells by Simultaneous Modulation of the Apaf-1/Caspase, AKT/MAPK and COX-2/NF-κB Signaling Pathways |
| - | in-vitro, | NPC, | NA |
| 8176- | Las, | In Vitro and In Vivo Anti-Cancer Activity of Lasiokaurin in a Triple-Negative Breast Cancer Model |
| - | vitro+vivo, | BC, | NA |
| 8177- | Las, | Lasiokaurin Regulates PLK1 to Induce Breast Cancer Cell G2/M Phase Block and Apoptosis |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 8179- | Las, | Lasiokaurin suppresses hepatocellular carcinoma proliferation and induces apoptosis via the JAK2/STAT3 pathway |
| - | in-vitro, | HCC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:14 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid